RecruitingPhase 2

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

China50 participantsStarted 2024-12-30

Plain-language summary

A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Able to understand the procedures of this trial and provide written informed consent voluntarily;
✓. Age ≥ 18 years, male or female;
✓. On a stable hemodialysis regimen at a frequency of two or three times per week for at least 12 weeks prior to the screening visit;
✓. Serum phosphorus within the trial-required range.

Exclusion criteria

✕. Any history of inflammatory bowel disease or diarrheal irritable bowel syndrome;
✕. Pregnant or breastfeeding;
✕. Any history of a parathyroid intervention;
✕. Diarrhea or loose stools occurred within 1 week prior to randomization.

What they're measuring

To preliminarily evaluate the efficacy of JMKX003002 in decreasing serum phosphorus of ESRD patients on hemodialysis

Timeframe: 4 weeks

Trial details

NCT IDNCT06664125

SponsorJemincare

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-06-30

Contact for this trial

Jing Xu

0086-020-87755766 xujing2@jemincare.com

View on ClinicalTrials.gov More Hyperphosphatemia trials